Trevi Therapeutics, Inc. (TRVI) Net Income (Loss) Attributable to Parent USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Trevi Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • Trevi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$10.9 M, a 70.3% decline year-over-year.
  • Trevi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$33.6 M, a 18.9% decline year-over-year.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.1 M, a 0.3% increase from 2022.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$29.2 M, a 14.1% increase from 2021.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$33.9 M, a 3.61% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$33.6 M -$10.9 M -$4.5 M -70.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$29.1 M -$7.82 M -$2.32 M -42.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-20
Q3 2023 -$26.7 M -$7.7 M +$568 K +6.87% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$27.3 M -$7.15 M +$907 K +11.3% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$28.2 M -$6.4 M +$928 K +12.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$29.2 M -$5.51 M +$3.02 M +35.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$32.2 M -$8.27 M -$1.01 M -13.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$31.2 M -$8.05 M +$1.74 M +17.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$32.9 M -$7.33 M +$1.04 M +12.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$33.9 M -$8.52 M +$1 M +10.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$34.9 M -$7.26 M +$123 K +1.67% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$35.1 M -$9.79 M -$2.41 M -32.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$32.7 M -$8.37 M +$102 K +1.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$32.8 M -$9.52 M -$2.99 M -45.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$29.8 M -$7.38 M -$13 K -0.18% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$29.8 M -$7.38 M -$38 K -0.52% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$29.7 M -$8.47 M -$3.67 M -76.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$26.1 M -$6.54 M -$555 K -9.28% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$25.5 M -$7.37 M -$1.71 M -30.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$23.8 M -$7.35 M -$2.49 M -51.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$21.3 M -$4.8 M -$751 K -18.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$20.5 M -$5.98 M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$5.65 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$4.86 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$4.05 M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.